Bergamo Acquisition Corp. (BGMO)

[notoriousinvestor]

Business Description 432 Reasons for BGMO to invest in VSTA
VistaGen Therapeutics Inc. is biotechnology company harnessing the revolutionary power of human pluripotent stem cell technology for drug rescue and cell therapy.

VistaGen's drug rescue activities involve the combination of its human pluripotent stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of small molecule drug candidates that pharmaceutical companies have discontinued during preclinical development ("put on the shelf") due to heart or liver toxicity, despite promising efficacy data. VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube(TM), is based on directed differentiation (development) of human pluripotent stem cells into multiple types of mature cells. With heart cells produced from stem cells, VistaGen has developed CardioSafe 3D(TM), a three-dimensional biological assay (screening) system the company believes is capable of predicting the human cardiac effects, both toxic and non-toxic, of new drug candidates, long before they are tested in humans. VistaGen's immediate goal is to leverage CardioSafe 3D(TM) to generate and monetize a pipeline of small molecule drug candidates through drug rescue collaborations. VistaGen intends to expand its drug rescue capabilities by introducing LiverSafe 3D(TM), a human liver cell-based toxicity and metabolism bioassay system. In collaboration with Dr. Gordon Keller, recently named a "Top 25 Transformational Canadian" for his pioneering stem cell research and technology, VistaGen is also advancing pilot preclinical development of large market cell therapy programs, including cartilage, heart and liver repair.